Official Title
Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI® Vaccine to Prevent SARS-CoV-2 Infection
Brief Summary

The purpose of this study is to assess the efficacy of RUTI® vaccine preventing SARS-CoV-2 infection (COVID-19) in healthcare workers.

Detailed Description

The aim of this study is to assess the efficacy of RUTI® vaccine preventing SARS-CoV-2
infection (COVID-19) in healthcare workers. The study will include a comparison between
placebo and RUTI® vaccine.

Unknown status
COVID-19
SARS-COV2

Biological: RUTI® vaccine

Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.

Biological: Placebo

Physiological serum, 0.9% NaCl, will be used as a placebo

Eligibility Criteria

Inclusion Criteria:

1. Sign the Informed Consent before initiating the selection procedures.

2. Healthcare system workers working in contact with subjects potentially infected with
SARS-CoV-2.

3. People ≥ 18 years.

4. Willingness to meet the requirements of the protocol.

5. Negative Rapid Serological Test of SARS-CoV-2

6. The participant must agree to use effective contraceptive methods during the study
period, in case of childbearing age.

Exclusion Criteria:

1. Previous SARS-CoV-2 infection

2. Pregnancy. Pregnancy test will be performed in case of doubt.

3. Breastfeeding.

4. Suspected of active viral or bacterial infection.

5. Symptoms compatible with COVID-19, despite a negative polymerase chain reaction (PCR)
test.

6. Vaccination in the last 4 weeks or planned vaccination during the study period, except
for influenza vaccine.

7. Participation in a research that requires experimental intervention (does not include
observational studies) in the previous month before signing the Consent or during the
study.

8. Severely immunocompromised people. This exclusion category includes:

1. Subjects with human immunodeficiency virus (HIV-1).

2. Neutropenic subjects with less than 500 neutrophils / mm3.

3. Subjects with solid organ transplantation.

4. Subjects with bone marrow transplantation.

5. Subjects undergoing chemotherapy.

6. Subjects with primary immunodeficiency.

7. Severe lymphopenia with less than 400 lymphocytes / mm3.

8. Treatment with any anti-cytokine therapy.

9. Oral treatment with steroids, defined as daily doses of 10 mg prednisone or
equivalent for more than 3 months.

9. Malignancy, or active solid or non-solid lymphoma from the previous two years.

10. BCG vaccination in the last 1year.

11. Soy allergy.

12 Chloroquine or hydroxychloroquine administration in the last two weeks.

13. Direct involvement in the design or execution of the RUTICOVID19 clinical trial.

14 Retirement, transfer, long-term leave (> 1 month) due to scheduled surgery or any other
event that makes it impossible to work in person at your health center during the months
following the recruitment to the study.

15. Employee at the health center <22 hours per week.

16. Do not have a smartphone.

17. Detection by the researcher of lack of knowledge or willingness to participate and
comply with all requirements of the protocol.

18. Any other findings that, at the discretion of the researcher, may compromise compliance
with the protocol or that may influence significantly the interpretation or the results of
the effects of the vaccine.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Spain
Locations

Hospital Universitari Germans Trias i Pujol UBP Riscos Laborals
Badalona, Barcelona, Spain

Hospital de la Santa Creu i Sant Pau
Barcelona, Spain

Contacts

Pere-Joan Cardona, MD, PhD
+34 93 033 0527 - 6400
pjcardona@igtp.cat

Pere-Joan Cardona, MD, PhD, Study Chair
IGTP

Fundació Institut Germans Trias i Pujol
NCT Number
MeSH Terms
COVID-19